Vaccine "renaissance" attracts huge new venture investments
The New York Times examines the surge in venture backing for biotechs involved in infectious disease research. VCs ponied up $192 million for the field in the first quarter of this year, an amount that could translate into an $800 million wager over the course of the year. Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, says the burst of new research and investment mark a renaissance of the vaccine business, though he notes that there's still no vaccine for HIV yet. It's all good for companies like Genocea, a start-up working on cheap therapies to combat viruses and bacteria.
- here's the article from The New York Times
Related article:
Gates adds $287M to HIV vaccine research Report
Comments
Vaccines are also useful against autoimmune disease. I went to dozens of doctors for relief of my symptoms and obtained none, so I followed my scientific training to utilize myself as a human guinea pig. Bottom line: dozens and dozens of injections of mumps, measles, and rubella vaccine (even daily, for weeks at a time) are safe and effective. The effect is even greater if augmented with vaccines containing live varicella virus and other live viruses. Randy Crawford, 3701 Second St. #10, Coralville, Iowa 52241 (319)400-2837
Vaccines are also useful against autoimmune disease. I went to dozens of doctors for relief of my symptoms and obtained none, so I followed my scientific training to utilize myself as a human guinea pig. Bottom line: dozens and dozens of injections of mumps, measles, and rubella vaccine (even daily, for weeks at a time) are safe and effective. The effect is even greater if augmented with vaccines containing live varicella virus and other live viruses. Randy Crawford, 3701 Second St. #10, Coralville, Iowa 52241 (319)400-2837
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends

